Saturday 17 October 2026
Export CERS’s income statement to Excel — free account
Cerus Corporation
CERS Healthcare Medical Devices
In the quarter to June 2026, revenue grew 5.28%, EPS grew 50.3%, free cash flow fell 20.9% and total debt fell 23.5%, each against the same quarter a year earlier.
2.20
0.06
−2.65%
Follow CERS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.36 | 1.44 | 1.68 | 1.35 | |
P/FCF ratio |
0.00 | 0.00 | 354.35 | 1,815.53 | |
P/Operating CF |
(220.09) | (115.89) | 63.33 | 158.28 | |
P/B ratio |
8.28 | 5.17 | 6.04 | 4.90 | |
Price to Tangible BV |
8.44 | 5.28 | 6.17 | 5.01 | |
EV/Sales |
2.40 | 1.46 | 1.68 | 1.38 | |
EV/EBITDA |
9,004.57 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
245.88 | 135.92 | 81.38 | 87.33 | |
EV/FCF |
(324.93) | (293.71) | 355.26 | 1,853.58 | |
Quick Ratio |
1.02 | 1.02 | 1.12 | 1.22 | |
Current Ratio |
1.83 | 1.63 | 1.73 | 1.89 | |
Net Debt/EBITDA |
(6.19) | 47.38 | (4.07) | 3.95 | |
Debt/Assets |
31.64% | 38.06% | 37.81% | 39.46% | |
Debt/Equity |
0.92 | 1.24 | 1.29 | 1.36 | |
Asset Turnover |
1.19 | 1.14 | 1.11 | 1.12 | |
Operating CF/Net income |
0.91 | 1.86 | (2.84) | (101.42) | |
Capex/Depreciation |
(1.89) | (0.52) | (3.33) | (4.80) | |
Interest Coverage |
(1.08) | (0.19) | (0.33) | 0.58 | |
Research and Development Expense of Revenue |
22.73% | 24.26% | 25.38% | 26.27% | |
Selling, General and Administrative Expense of Revenue |
36.12% | 33.31% | 32.25% | 30.91% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
8.68% | 8.19% | 7.63% | 9.34% | |
Graham Net Nets |
0.04 | 0.06 | 0.04 | 0.05 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.20%) | (2.75%) | (3.89%) | (5.25%) | |
Free Cash Flow Yield |
(0.31%) | (0.34%) | 0.28% | 0.06% | |
Revenue per Share |
0.32 | 0.31 | 0.34 | 0.31 | |
Operating CF per Share |
(0.01) | (0.02) | 0.03 | 0.01 | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.02) | (0.02) | 0.03 | 0.00 | |
Cash per Share |
0.28 | 0.41 | 0.43 | 0.41 | |
Shareholders Equity per Share |
0.35 | 0.35 | 0.34 | 0.32 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.35 | 0.35 | 0.34 | 0.32 | |
Free Cash Flow |
(3.53) | (3.28) | 4.89 | 0.09 | |
Working Capital |
71.52 | 67.96 | 73.58 | 78.69 | |
Capital Expenditures |
(0.87) | (0.23) | (1.31) | (1.83) | |
Net Current Asset Value |
22.84 | 20.72 | 17.49 | 14.15 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.02 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
31.18 | 27.83 | 30.08 | 27.07 | |
Average Payables |
32.02 | 29.73 | 24.85 | 20.67 | |
Average Inventory |
60.17 | 54.64 | 47.13 | 44.84 | |
Average Assets |
209.13 | 214.84 | 211.39 | 202.36 | |
Average Common Equity |
63.44 | 62.26 | 60.93 | 58.24 |
Columns are period end dates